about
Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous HistologiesPhase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for responsePhase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.Gastro-intestinal stromal tumours: a review of current management options.Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer.Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer.Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.Personalized medicine for non-small-cell lung cancer.Crizotinib in the management of advanced-stage non-small-cell lung cancer.Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).Applicability of BALAD score in prognostication of hepatitis B-related hepatocellular carcinoma.Ten-year review of survival and management of malignant glioma in Hong Kong.Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma.Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers.Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy.Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer.Controversies in the systemic treatment of nasopharyngeal carcinoma.Frameless stereotactic radiosurgery for brain metastases: a review of outcomes and prognostic scores evaluation.Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer.PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.Fertility preservation in young cancer patients as a springboard to address the needs of this unique population.Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study.A feasibility study on using tablet personal computers for self-reported symptom assessment in newly diagnosed lung cancer patients.Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.Adherence to the World Cancer Research Fund/American Institute for Cancer Research Guideline Is Associated With Better Health-Related Quality of Life Among Chinese Patients With Breast Cancer.Overview of current systemic management of EGFR-mutant NSCLC.Low expressions of ASS1 and OTC in glioblastoma suggest the potential clinical use of recombinant human arginase (rhArg).Quality of life of young Chinese breast cancer patients after adjuvant chemotherapy.Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas.Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled TrialHemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiationPrimary cardiac sarcomas: A multi-national retrospective reviewA phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinomaPrognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinomaAre we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?Lung cancer: dropping bars or rising hoops--phase III outcomes of NSCLC
P50
Q26766254-04EDC4F6-1BC8-454A-AF93-06CF6EF7E63FQ33416051-08F6E2A4-DD78-43C6-8FD7-4D7BADD16B0EQ33422744-2768F0DC-E991-4BA6-B784-98888778D867Q33434141-403606B2-B243-4A15-9DA9-9E2C1DB02FDBQ36727890-F0B1BB3B-E366-4D59-B92E-BCFDE4CDBB4DQ37325872-7B8428E3-8E90-4DF0-81F1-42A843C2600FQ37443898-FE281983-3DB8-4629-B50C-DDB2EFFE32FCQ37722656-06478D2C-980A-4E2B-9683-BB4C35472D4CQ37799826-57B3B3F1-7165-48D2-A6EA-6C9116236ECFQ38372437-1D171C18-8F29-45C2-939E-03998B366340Q38385856-FF3ED6C1-8683-4275-ADD3-7856CCA9263DQ38386410-90A47F64-006E-4822-8D12-DABCE3C4DFD9Q39026523-AADDCAE0-C65B-447F-A158-B7E86119D693Q39105272-DD75CB66-7CBB-4D7E-A04E-6D0B93A3934CQ39896037-97CEA573-7BA2-47F0-965D-182C5F92705BQ41163292-47B30D0E-456D-43A5-A39B-03373A2194B7Q41758054-6BC25D2D-9AB1-4BD4-9817-93E2A7C54BFEQ41892153-A864B0B0-B660-47A9-B46E-66A37EB15319Q45062569-399C53D0-4698-403C-B96F-E26FF85CCAF1Q47220829-E23DFE27-D361-4381-8836-9B382E8F0ED0Q47267048-0516742C-80AC-4A8C-ABB1-71E95F5048D2Q47803178-574944FC-729E-4E90-BB06-74450FF6ED05Q48158555-D6D408A7-B6E1-4A28-A7FE-15537664FCA8Q49954412-EAF3FA35-16A7-4FB6-8C84-319BA6CF1B50Q50187428-533D56CE-1E68-45C0-B2AD-73133CB08091Q52593788-4B30C08D-30D4-4183-864E-B3CC76ACF895Q52647899-BE56E143-C711-47B7-B71A-10B1482B517EQ52663675-3B75CAE9-59C5-4ADB-A37F-5747CE6E1126Q52692616-C2404B12-E0A1-406E-9009-4ADD511E2088Q53064344-80F137B0-E9E6-419F-8738-C91C131178A9Q54942232-A96031E6-11AA-44D4-8E7C-09A886BA56E6Q55686663-1A516336-FC66-4421-B78B-6CB1A73A813FQ57176613-C0790D15-0F30-486C-9EEE-0E6901EDB94BQ59647283-41613EBD-D2E5-4BF8-8A3D-AF4D60A2037DQ61455451-ED63939A-9B10-4949-9E42-72548F95C724Q64056806-6C9E1CC0-67B5-41C7-8331-FDC59053133DQ82584556-64A4142A-760E-4D78-91EB-C6B7B558C954Q83387461-D1DBF94F-66D7-4D79-94F1-2C9762A1B2F3Q86986567-B92FB265-0F55-4312-9B86-15923E0DA5DDQ87903213-CE4A874C-E9FB-4C13-B1C7-0BDB3205F96A
P50
description
researcher ORCID ID = 0000-0002-6607-1106
@en
wetenschapper
@nl
name
Herbert Loong
@ast
Herbert Loong
@en
Herbert Loong
@es
Herbert Loong
@nl
type
label
Herbert Loong
@ast
Herbert Loong
@en
Herbert Loong
@es
Herbert Loong
@nl
prefLabel
Herbert Loong
@ast
Herbert Loong
@en
Herbert Loong
@es
Herbert Loong
@nl
P1153
15725325400
P31
P496
0000-0002-6607-1106